Endocrinology & Metabolism

FDA investigating testosterone’s cardiovascular risks

Posted on: 03/02/2014 - 14:00

The Food and Drug Administration is reassessing the cardiovascular safety of approved testosterone treatments and urged physicians and patients to report side effects. Two recent observational...

Field of Interest: Cardiology

Type: News Item

FDA investigating testosterone’s cardiovascular risks

Posted on: 03/02/2014 - 14:00

The Food and Drug Administration is reassessing the cardiovascular safety of approved testosterone treatments and urged physicians and patients to report side effects. Two recent observational...

Field of Interest: Geriatrics

Type: News Item

The politics of food addiction: Who wins, who 'loses'

Posted on: 28/01/2014 - 17:15

ATLANTA – It’s too soon to disrupt current obesity treatment by declaring food addiction to be a clinical condition, according to Dr. Paul Fletcher. "If we are to employ [the term] food...

Field of Interest: Endocrinology

Type: News Item

One health system cut diabetes events, with set patient measures and cash for physicians

Posted on: 23/01/2014 - 19:30

An incentivized, system-based approach to improve care for patients with diabetes and other chronic diseases appeared to pay off after just 3 years by significantly cutting the incidence of adverse...

Field of Interest: Endocrinology

Type: News Item

MicroRNA screening might reveal pancreatic cancer

Posted on: 21/01/2014 - 22:20

Researchers have identified two novel panels of microRNAs that eventually might be used to screen patients for pancreatic cancer, distinguishing affected patients from healthy individuals and from...

Field of Interest: Endocrinology

Type: News Item

‘Obesity paradox’ refuted

Posted on: 15/01/2014 - 22:00

Mortality is not lower among adults with diabetes who were overweight or obese at diagnosis than among those who were of normal weight, as has been suggested by proponents of the "obesity...

Field of Interest: Endocrinology

Type: News Item

FDA approves dapagliflozin for type 2 diabetes

Posted on: 08/01/2014 - 20:20

Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been approved for the treatment of type 2 diabetes with a requirement that the manufacturer conduct postmarketing studies that address...

Field of Interest: Endocrinology

Type: News Item

Postpartum care after gestational diabetes is preconception care as well

Posted on: 07/01/2014 - 20:05

WASHINGTON – The rise in gestational diabetes cases demands new strategies for active postpartum care that will not only assist with prevention of type 2 diabetes, but will also prepare women for...

Field of Interest: Endocrinology

Type: News Item

Body fat and cardiovascular risk: Location, location, location!

Posted on: 09/12/2013 - 15:05

DALLAS – It’s not obesity per se that affects cardiovascular risk, it’s where that excess body fat is stored, according to the results of a novel adipose tissue–imaging study. Excess visceral...

Field of Interest: Cardiology

Type: News Item

Analysis: No such thing as ‘benign’ obesity

Posted on: 02/12/2013 - 22:00

"Metabolically healthy" overweight and obese patients may carry the same short-term risk as normal-weight patients for all-cause mortality and cardiovascular events, but their weight puts...

Field of Interest: Cardiology

Type: News Item

Newsletters

Stay informed on our latest news!

You are here

Newsletters

Latest Newsletters